Activist investor Elliott Investment Management has reportedly built a sizable stake in Bio-Rad Laboratories (BIO). According to the Wall Street Journal, Elliott is aiming to push management to improve shareholder value and revive the struggling BIO stock. BIO shares have fallen more than 70% from their 2021 peak and are already down roughly 18% in 2026. Looking ahead, Elliott’s involvement could be a positive catalyst for BIO stock as it may increase pressure on management to improve operations. However, this is unlikely to become a quick turnaround story unless Bio-Rad delivers improved core business growth alongside any activist-driven changes.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For context, Bio-Rad Laboratories develops lab instruments, diagnostic systems, reagents, and software used by pharmaceutical companies, biotech firms, hospitals, universities, and research labs worldwide.
What This Could Mean for Bio-Rad
Elliott Investment Management is one of the world’s largest activist hedge funds and is known for pushing struggling companies to improve performance and increase shareholder value. The firm often pressures management to cut costs and improve operations. That’s why Elliott’s investment in Bio-Rad Laboratories could be important for the company and its stock. If Bio-Rad improves operationally, Elliott could encourage strategic partnerships, asset sales, or even position the company as a potential takeover candidate.
Additionally, Elliott is also a major investor in Sartorius AG (SOAGY), the German life-science and biopharma equipment supplier in which Bio-Rad Laboratories holds a large strategic stake. This overlap is important because Elliott already understands Sartorius’ business deeply and reportedly views it as a high-quality company with strong long-term growth potential.
However, the exact size of Elliott’s stake in Bio-Rad and the firm’s specific plans have not been disclosed publicly. In addition, Bio-Rad remains tightly controlled by its founding family through super-voting shares, which could limit Elliott’s influence compared with other activist campaigns.
Bio-Rad’s Q1 Performance
Recently, Bio-Rad Laboratories reported mixed Q1 2026 results. Total net sales rose 1.1% year-over-year, but declined 4.2% on a currency-neutral basis, reflecting weakness across both its Life Science and Clinical Diagnostics businesses.
Overall, demand for biotech and life-science tools has remained weak since the post-pandemic slowdown, but spending trends are beginning to stabilize, which could support a broader recovery in Bio-Rad’s core business. Meanwhile, management forecast 2026 operating margins of just 10%–12%, well below historical levels and far behind many industry peers that often generate margins above 30%.
What Is the Price Target for BIO Stock?
Turning to Wall Street, BIO stock has a Moderate Buy consensus rating based on 1 Buy and two Holds assigned in the last three months. At $303.33, the average Bio-Rad stock price target implies a 22.54% upside potential.
